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than an increase in gray matter.   Some have reported increases in beta-amyloid 
plaques in affected persons which can induce gliosis.  These observations have led us 
to begin a study to verify the presence of beta-amyloid plaques and cell density to 
better understand the changes Hsa21 produces in the brain. Despite relatively extreme 
pathological changes in the brain the behavior of Hsa21 carriers did not exhibit 
significant memory impairments as compared to controls. There was a trend towards 
memory impairment.  However, some of the subjects appeared to be hypoactive (a trait 
associated with Down Syndrome) that may have confounded our test that was dependent on 
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 Down syndrome is caused by trisomy of human chromosome 21 (Hsa21) and often leads 
to Alzheimer’s disease in affected individuals. The Tc1 mouse model contains a copy of Hsa21 
in its genome, and is therefore trisomic for the genes it contains to manifest as a Down syndrome 
mouse model. Transmission of Hsa21 to offspring generations occurs at a low frequency with 
fertility rates decreased in comparison to control mouse lines.  
This experiment has verified that presence of Hsa21 causes a significant increase from 
normal brain weight. Hsa21 carriers demonstrated reductions in the number and length of 
dendritic projections and the number spines on cortical neurons suggesting that the increase in 
brain size may have been due to changes in glial cell proliferation rather than an increase in gray 
matter.   Some have reported increases in beta-amyloid plaques in affected persons which can 
induce gliosis.  These observations have led us to begin a study to verify the presence of beta-
amyloid plaques and cell density to better understand the changes Hsa21 produces in the brain. 
Despite relatively extreme pathological changes in the brain the behavior of Hsa21 carriers did 
not exhibit significant memory impairments as compared to controls. There was a trend towards 
memory impairment.  However, some of the subjects appeared to be hypoactive (a trait 
associated with Down Syndrome) that may have confounded our test that was dependent on 
normal motor function.  Studies of spontaneous activity are now underway.  
Purpose: 
Down syndrome (DS) encompasses the majority of live born chromosomal abnormalities 
and results in cognitive impairment along with other debilitating health problems (Gardiner et al, 
2010). DS is caused by trisomy, or three copies versus the normal two, of chromosome 21 
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(Hsa21). People with DS exhibit impaired ability to put words together, poor ability to recall 
events or objects (explicit long-term memory), as well as deficient verbal short-term memory. 
A feature frequently seen in DS is the presence of Alzheimer’s (AD) symptoms of 
memory impairment and neuropathy, including the presence of neurofibrillatory tangles and 
beta-amyloid plaques in the brains of 50% of people with DS at thirty years of age (Rueda et al, 
2010). Interestingly, both DS and AD are influenced by chromosome 21, which not only causes 
DS when in a trisomy, but also contains an extra copy of the gene for the amyloid-precursor 
protein (APP) (Palmer, 2011). The subsequent overexpression of the APP gene leads to an 
increased risk for AD in people with DS. As neuronal damage from AD neuropathy is 
irreversible, it is vital to find and stop the damage from AD in DS as quickly as possible.  
The overlap in pathology between people with AD and people with DS suggests that this 
is where the current research on DS should be directed. Studies in this area could open doors to 
improving cognitive abilities in people with DS, and subsequently, extend and improve their 
overall quality of life. The exploration of the present study is focused on this goal. 
 The Tc1 mouse model of DS from Jackson Laboratories offers an excellent opportunity 
to explore prenatal aspects in DS. These mice are genetically modified to produce offspring with 
DS (O’Doherty et al, 2005). The main advantage of using the Tc1 mouse is that the first 21 days 
postnatal corresponds with the developmental cycle of a human still in utero (Sherwood and 
Timiras, 1970). Utilizing this correlation between human and rodent development allows us to 
directly observe brain development for comparison to stages of human in utero development, and 
identify early behavioral and brain development changes and potential therapeutic interventions. 
Therefore, using this particular mouse model to try to identify underlying causes and possible 
4 
 
routes for further investigation is nearly ideal in the study of Down syndrome.  Therefore, the 
purpose of this experiment was to compare neurological and behavioral similarities between 
Down syndrome to those of Alzheimer’s disease using a mouse model of DS.  
Research Design: 
Validation of the mouse model 
In this the first part of this experiment, a mouse model for DS, the B6129S-
Tc(Hsa21)1TybEmcf/J from Jackson Laboratories, was compared with non-diseased control 
mice (mouse model C-57 BL/6J) (The Jackson Laboratory, Bar Harbor, ME). The Tc1 model is a 
transchromosomic mouse that carries an extra copy of human chromosome 21 (Hsa21) 
(O’Doherty et al 2005). As compared to other mouse models for DS that contain trisomy of 
mouse chromosomes, the Tc1 model expresses trisomy exclusively for the genes on the inserted 
chromosome, Hsa21. O’Doherty et al created this transchomosomic model by inserting 
approximately 90% of Hsa21 into mouse embryonic stem cells, resulting in a fairly stable and 
transmittable germline exhibiting chimeric features also seen in human DS mosaicism (both 
trisomic and normal cells exist in the same specimen).  
In the first phase of this experiment, Tc1 mice were put through a longitudinal study to 
evaluate learning and memory.  These tests were completed at 25 days, 42 days, 90 days, 12 
months, and 24 months and consisted of training for the step-down test for inhibitory 
avoidance/learning followed by a 24 hour and 7 day memory retention test (using the methods of 
Izquierdo, Fiorenza, Rosa, Myskiw; 2012). Additional tests completed at 90 days including the 
open-field and dark-light tests. All of the tests were compared to age matched control mice. Two 
female Hsa21 positive female breeders and their mates were tested at one year of age with the 
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step-down test of test of inhibitory avoidance (training, 24 hour retest, and 7 day retest), open-
field, dark-light, and spontaneous alteration t-maze to assess hippocampal functioning (using the 
methods of Gerlai, 1998). 
Along with behavior tests the neuropathy of the Tc1 model was addressed. After the 90 
day testing was completed, mice were euthanized and sample of brain,  tissue from the tail and 
ear (for genotyping), and blood samples were obtained. Genotyping via polymerase chain 
reaction (PCR) and gel electrophoresis was completed to identify mice that were carriers of 
Hsa21. Histology work for AD pathology, represented by beta-amyloid plaques and tangles, 
reduced cell count, and lowered spine numbers were completed. These stains consisted of 
Bielschowsky’s stain (beta-amyloid plaques), cresyl violet (cell density), and golgi-thionin 
(dendrite size and counting the number dendritic spines). 
Results: 
Identification of the transgene at 205 base pairs (bp) was completed using PCR (see: 
Figure 1). An internal positive control band at 324 bp needed to be present in all subjects to be 
considered a valid PCR result. From Figure 1 it can be seen that subject DS07 carries the 
transgene, Hsa21, and is therefore a positive carrier. The rest of the subjects in the sample gel 
were negative for the Hsa21 transgene. Out of the 18 offspring of Tc1 breeders, three mice were 
found to be positive carriers for Hsa21. Reproduction rates overall were dramatically lower (1 to 
6 mice per litter) than most mouse strains (8-16) in our colony.   PCR and gel electrophoresis 
were completed for all subjects. Tc1 results are shown in Table 1 along with relative brain 
weights as compared to body weight on the day of sacrifice. Golgi-thionin staining revealed 
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dramatic decreases in both the number and length of dendrites in the cortex as well as the 
number of spines in the Hsa21 carriers compared to noncarriers, (see Figure 2). 
 
 
Figure 1. Sample of gel electrophoresis of PCR products.  In this example only  DS07 carries the  
transgene Hsa21. 
 
Behavioral data for the step-down test of inhibitory avoidance beginning at 25 days of 
age for subjects DS07-DS24 and through 90 days of age is shown in Table 2. Breeders DS28-
DS30 were trained at one year of age and completed a 24 hour and 7 day retest. The step-down 
latency at each time point was found by subtracting the initial training time from the time at data 
points from 24 hour, 7 day, 42 day, and 90 day retests. The average step-down latency of Hsa21 
carriers and noncarriers (see Table 1) was calculated and (see Figure 3). The mean number of 
boli (an index of emotionality) at each test point was also compared between Hsa21 carriers and 






Table 1. Genotyping results and relative brain weights for Tc1 subjects. The average relative 
brain weight of Hsa21 carriers (20.12 g) was significantly greater than that of Hsa21 
negative mice (16.23 g) with t(20) = 3.282, p < .05. 
 
Code Hsa21 Age Gender Relative Brain Weight 
DS07 + 90 d f 19.86 
DS08 - 90 d f 17.85 
DS09 - 90 d f 19.00 
DS10 - 90 d m 15.59 
DS11 - 90 d m 14.13 
DS12 - 90 d f 19.78 
DS13 - 90 d m 15.21 
DS14 - 90 d m 11.20 
DS15 - 90 d m 15.19 
DS16 - 90 d m 14.87 
DS17 + 90 d f 22.94 
DS18 - 90 d m 14.07 
DS19 - 90 d m 13.78 
DS20 + 90 d f 21.46 
DS21 - 90 d f 19.25 
DS22 - 90 d f 19.35 
DS23 - 90 d f 17.31 
DS24 - 90 d f 17.70 
DS27 + 1 yr f 17.69 
DS28 + 1 yr f 18.67 
DS29 - 1 yr m 16.39 
DS30 - 1 yr m 15.32 
 
 








Figure 2. Golgi thionin staining of neurons in a control, Tc1 control, and Tc1 Hsa21 carrier. The 
Hsa21 carrier demonstrates somas in the cortex, but extensively reduced axon 







Table 2. Raw data from step-down test of inhibitory avoidance learning. 
Code Training 24 hr retest 7 d retest 42 day retest 90 day retest 
time (s) boli time (s) boli time (s) boli time (s) boli time (s) boli 
DS07 36.88 0 300.00 5 99.09 2 166.1 3 300 4 
DS08 13.78 0 148.41 0 270.09 2 81 1 300 3 
DS09 11.72 0 11.59 0 48.01 0 75 1 39.03 2 
DS10 186 1 300.00 1 300 4 215 2 178.25 1 
DS11 10.85 0 28.00 0 108.4 2 259 4 231.6 3 
DS12 17.47 0 42.46 1 79.88 1 32.81 0 57.25 0 
DS13 21.53 0 39.00 0 300 1 300 1 286.19 2 
DS14 44.44 1 300.00 1 300 1 200.34 1 300 3 
DS15 29.08 0 268.62 4 187.6 1 74.85 1 78.22 2 
DS16 266.47 0 300.00 1 300 3 300 5 300 3 
DS17 49.31 0 99.63 1 53.31 1 27.62 1 23.13 0 
DS18 70.47 1 300.00 2 300 0 300 3 300 5 
DS19 14.04 0 183.88 2 106.88 1 259.57 1 219.65 3 
DS20 36.58 0 111.87 3 121.5 0 241.94 1 234.84 4 
DS21 29.31 0 99.83 2 99.8 0 113.09 1 97.06 1 
DS22 64.18 0 101.00 1 60.31 0 262.63 2 300 6 
DS23 16.12 2 8.96 0 151.15 0 91.75 1 283.19 3 
DS24 21.78 0 243.22 1 138.97 0 300 5 300 2 
DS27 5.00 0 300.00 3 300.00 6 - - - - 
DS28 57.60 0 202.47 0 16.84 0 - - - - 
DS29 6.30 0 300.00 6 300.00 7 - - - - 





Figure 3. Step down latency adjusted from initial training step down time. Hypomotor activity 
may have influenced increased step down latency in Hsa21 positive subjects during the 
24 hour retest period. Trends towards memory impairment of Hsa21 carriers as 





Figure 4. Mean number of boli at each test point for Hsa21 noncarriers (negative) and carriers 
(trisomy positive). 24 hour and 7 day retest data indicates increased anxiety in Hsa21 




 This study has successfully demonstrated that the Hsa21 gene does get passed on to 
offspring generations in mice in a way that is similar to human Down syndrome. However, the 
transmission rate of the gene was very low (16.7%) and fertility rates of the Tc1 females were 
also lower than other mouse strains. The profound decrease in dendrite length and projections in 
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the brain (see Figure 2) suggests that addition of Hsa21 into the mouse genome produces severe 
neurological effects consistent with human Down syndrome. This observation is further 
supported by statistically significant changes in relative brain weight of Hsa21 positive mice 
compared to controls. 
 Although trends in behavioral data were noted (see Figures 3 and 4), the observations 
were not statistically significant.  This is not surprising given our difficulty in breeding large 
numbers of  Hsa21 positive subjects for testing.  The number of positive subjects (N=5) 
compared to controls (N=18) limited the statistical power of our tests.  For this reason we plan to 
obtain new breeders in August of 2013 and continue the project beyond the grant period.  We 
feel this is justified given the very promising changes noted in the brain and their similarity to 
the human form of Down syndrome.   In addition, we also suspect that our use of an activity 
dependent memory test may have skewed the behavioral data.  Since evidence of memory was 
scored as an increase in immobility on the test platform (failing to step down) any reduction in 
activity levels would have appeared as better retention.  We have completed tests of activity 
(open-field) and anxiety (light-dark test) and are in the process of training scorers to analyze the 
data.  We have also completed staining with cresyl violet (to verify neuron numbers) and a beta-
amyloid staining.  We plan to score these slides next fall.  The data from these studies will be 
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